Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing …
Akari TX /
Press Release
NEW YORK and LONDON, September 22, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
NEW YORK and LONDON, September 12, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics Announces $12.75 Million Registered Direct Offering
NEW YORK and LONDON, August 1, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
[Read more...] about Akari Therapeutics Narrows Pipeline Focus
Positive results from recent pre-clinical studies support the potential of long-acting PASylated® nomacopan to advance toward IND/IMPD for clinical trials in …
